ATE114474T1 - Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes. - Google Patents

Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.

Info

Publication number: ATE114474T1
Authority: AT; Austria
Prior art keywords: blood glucose; aica; lowering blood; ribosiden; administration
Prior art date: 1989-01-24

Application number

AT90903063T

Other languages

English (en)

Inventor

Harry E Gruber

Ronald E Tuttle

Clinton E Browne

Bheemarao G Ugarkar

Jack W Reich

Ernest Kurt Metzner

Paul J Marangos

Original Assignee

Gensia Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-24

Filing date

1990-01-24

Publication date

1994-12-15

1989-01-24 Priority claimed from US07/301,222 external-priority patent/US5082829A/en

1989-01-24 Priority claimed from US07/301,453 external-priority patent/US5200525A/en

1990-01-24 Application filed by Gensia Pharma filed Critical Gensia Pharma

1994-12-15 Application granted granted Critical

1994-12-15 Publication of ATE114474T1 publication Critical patent/ATE114474T1/de

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
239000008280 blood Substances 0.000 title abstract 3
210000004369 blood Anatomy 0.000 title abstract 3
239000008103 glucose Substances 0.000 title abstract 3
DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 title 1
210000005097 arteria cerebelosa anteroinferior Anatomy 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 abstract 4
RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 abstract 1
108010076278 Adenosine kinase Proteins 0.000 abstract 1
102100032534 Adenosine kinase Human genes 0.000 abstract 1
208000013016 Hypoglycemia Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
External Artificial Organs (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Prostheses (AREA)

AT90903063T 1989-01-24 1990-01-24 Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes. ATE114474T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/301,222 US5082829A (en)	1989-01-24	1989-01-24	AICA riboside prodrugs
US07/301,453 US5200525A (en)	1989-01-24	1989-01-24	Anti-seizure compounds
US40810789A	1989-09-15	1989-09-15

Publications (1)

Publication Number	Publication Date
ATE114474T1 true ATE114474T1 (de)	1994-12-15

Family

ID=27404800

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90903063T ATE114474T1 (de)	1989-01-24	1990-01-24	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.

Country Status (13)

Country	Link
EP (1)	EP0427799B1 (de)
JP (1)	JPH03504728A (de)
KR (1)	KR910700057A (de)
AT (1)	ATE114474T1 (de)
AU (2)	AU5086190A (de)
CA (1)	CA2008325A1 (de)
DE (1)	DE69014562T2 (de)
DK (1)	DK0427799T3 (de)
FI (1)	FI904694A7 (de)
IE (1)	IE75372B1 (de)
IL (1)	IL93164A0 (de)
NO (1)	NO904149L (de)
WO (1)	WO1990009163A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5214048A (en) *	1987-05-19	1993-05-25	Nippon Kayaku Kabushiki Kaisha	Oxetanocins
US5736531A (en)	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en)	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7776838B1 (en)	1987-10-28	2010-08-17	Wellstat Therapeutics Corporation	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5202459A (en) *	1989-11-07	1993-04-13	Nippon Kayaku Kabushiki Kaisha	Process for producing cyclobutane derivative
JPH0615556B2 (ja) *	1989-11-10	1994-03-02	旭化成工業株式会社	４―カルバモイル―１―β―Ｄ―リボフラノシル―イミダゾリウム―５―オレイト無水結晶
US5324730A (en) *	1990-05-24	1994-06-28	Nippon Kayaku Kabushiki Kaisha	Phenoxyphosphoryloxymethyl cyclobutyl purines
IL99124A (en) *	1990-08-10	1998-02-22	Gensia Pharma	Substituted imidazole analogs of aica riboside
US5236908A (en) *	1991-06-07	1993-08-17	Gensia Pharmaceuticals, Inc.	Methods of treating injury to the central nervous system
IL103294A0 (en) *	1991-09-30	1993-05-13	Gensia Pharma	Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
RU2153873C2 (ru) *	1994-08-09	2000-08-10	Кортендо АБ	Применение кетоконазола и родственных веществ в лекарствах, предназначенных для лечения диабета типа ii
AU6691798A (en) *	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (de) *	1997-03-07	2004-03-31	Metabasis Therapeutics, Inc.	Benzimidazolinhibitoren der Fructose 1,6-biphosphatase
WO1998039344A1 (en)	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) *	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
CN101125864A (zh) *	1998-09-09	2008-02-20	症变治疗公司	新的果糖1,6-二磷酸酶的杂芳族抑制剂
AU2003242500B2 (en) *	1998-09-09	2006-11-02	Metabasis Therapeutics, Inc.	Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
CZ297264B6 (cs)	1998-09-09	2006-10-11	Metabasis Therapeutics, Inc.	Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
US6756360B1 (en)	1998-12-24	2004-06-29	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000038666A2 (en) *	1998-12-24	2000-07-06	Metabasis Therapeutics, Inc.	A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
EP1607401A1 (de)	2000-03-08	2005-12-21	Metabasis Therapeutics, Inc.	Neue Aryl-Fructose-1,6-Bisphosphatase-Inhibitoren
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN101301294A (zh) *	2000-07-06	2008-11-12	症变治疗公司	Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
ES2192495B1 (es)	2002-03-21	2005-02-16	Universidad De Barcelona	Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
EP1752450A1 (de)	2005-08-01	2007-02-14	Merck Sante	Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
WO2008086341A1 (en) *	2007-01-09	2008-07-17	Pericor Therapeutics, Inc.	Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
EP2058308A1 (de)	2007-11-12	2009-05-13	Merck Sante	Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
EP2349284B1 (de) *	2008-10-03	2016-11-23	Pericor Therapeutics, Inc.	Behandlung von akuter decompensierter herzinsuffizienz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1535561A (fr) *	1966-06-18	1968-08-09	Ajinomoto Kk	Méthode de préparation de l'adénine, de ses dérivés et intermédiaires
US4575498A (en) *	1983-07-21	1986-03-11	Duke University	Method for restoring depleted purine nucleotide pools
FI875245A0 (fi) *	1986-03-27	1987-11-27	Harry Edward Gruber	Foerfarande foer oekande av utsoendringen av adenosin.
US4912092A (en) *	1986-03-27	1990-03-27	The Regents Of The University Of California	Methods for increasing extracellular adenosine and for stabilizing mast cells

1990
- 1990-01-24 JP JP2503252A patent/JPH03504728A/ja active Pending
- 1990-01-24 IL IL93164A patent/IL93164A0/xx unknown
- 1990-01-24 IE IE27490A patent/IE75372B1/en not_active IP Right Cessation
- 1990-01-24 FI FI904694A patent/FI904694A7/fi not_active Application Discontinuation
- 1990-01-24 EP EP90903063A patent/EP0427799B1/de not_active Expired - Lifetime
- 1990-01-24 WO PCT/US1990/000359 patent/WO1990009163A2/en not_active Ceased
- 1990-01-24 AT AT90903063T patent/ATE114474T1/de active
- 1990-01-24 DE DE69014562T patent/DE69014562T2/de not_active Expired - Fee Related
- 1990-01-24 AU AU50861/90A patent/AU5086190A/en not_active Abandoned
- 1990-01-24 CA CA002008325A patent/CA2008325A1/en not_active Abandoned
- 1990-01-24 DK DK90903063.7T patent/DK0427799T3/da active
- 1990-09-24 NO NO90904149A patent/NO904149L/no unknown
- 1990-09-26 KR KR1019900702149A patent/KR910700057A/ko not_active Withdrawn
1993
- 1993-12-13 AU AU52360/93A patent/AU5236093A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0427799A4 (en)	1991-07-24
DE69014562T2 (de)	1995-06-22
IE75372B1 (en)	1997-09-10
DK0427799T3 (da)	1995-05-08
IL93164A0 (en)	1990-11-05
WO1990009163A3 (en)	1991-01-24
NO904149L (no)	1990-11-26
NO904149D0 (no)	1990-09-24
CA2008325A1 (en)	1990-07-24
WO1990009163A2 (en)	1990-08-23
DE69014562D1 (de)	1995-01-12
EP0427799B1 (de)	1994-11-30
IE900274L (en)	1990-07-24
KR910700057A (ko)	1991-03-13
FI904694A0 (fi)	1990-09-24
EP0427799A1 (de)	1991-05-22
FI904694A7 (fi)	1990-09-24
JPH03504728A (ja)	1991-10-17
AU5086190A (en)	1990-09-05
AU5236093A (en)	1994-02-24

Publication	Publication Date	Title
DE69014562D1 (de)	1995-01-12	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
PL346520A1 (en)	2002-02-11	Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
DE60125734D1 (en)	2007-02-15	Neue aryl fructose-1,6-bisphosphatase inhibitoren
NO951592L (no)	1990-06-26	Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
HU907065D0 (en)	1991-05-28	Process for manufacturing pharmaceutical preparative of transdermal action containing 2-amino-6-(n-propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
GR3023432T3 (en)	1997-08-29	Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages
DE10199020I2 (de)	2004-05-06	Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
IL99290A0 (en)	1992-07-15	Nonaqueous fluorinated drug delivery vehicle suspensions
EP0306347A3 (en)	1990-10-03	Diagnosis and treatment of double-stranded rna deficiency states
NO882853D0 (no)	1988-06-28	Korreksjon med dobbeltraadet rna av unormale tilstander i immunkomplekser som er i omloep, og i monocytfunkjon.
IT8848262A0 (it)	1988-08-02	Dispositivo di supporto laterale, in particolare per l'arco mediano del piede
EP0354322A3 (de)	1990-06-13	Antidiabetische alpha-substituierte Phosphonate
ES2138729T3 (es)	2000-01-16	Metodos de diagnostico de la preeclampsia.
ES2080736T3 (es)	1996-02-16	Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
ATE107509T1 (de)	1994-07-15	Nusammensetzung mit udpg und anderen antitumormitteln zur behandlung von tumoren.
ATE501760T1 (de)	2011-04-15	E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
DE3650368D1 (de)	1995-09-21	Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
Senczuk et al.	1984	Toxicodynamic propertes of toluidines. Part II. Blood absorption of toluidines.
GB9818650D0 (en)	1998-10-21	Therapeutic compounds and methods of making and using the same
RU98120791A (ru)	2000-09-10	Способ диагностики, профилактики и коррекции неврологических и психических состоянии
UA29106A (uk)	2000-10-16	Спосіб лікування вібраційної хвороби
IT8621585V0 (it)	1986-04-18	Dispositivo per la guida in orizzontale della slitta, nei cestelli ed elementi in genere estraibili dei mobili.
ATE63692T1 (de)	1991-06-15	Ein gegenstand, geeignet zum blutkontakt, dessen herstellung und verwendungen.
UA29709A (uk)	2000-11-15	Спосіб лікування захворювань гастродуоденальної системи та суміш для його здійснення
UA34237A (uk)	2001-02-15	Спосіб діагностики туберкульозу